VEGFA and wet macular degeneration: Gene therapy with a single subretinal or intravitreal injection may offer longer-lasting effects in visual gains in both dry and wet AMD, hence reducing or eliminating the need for frequent intravitreal applications of VEGF inhibitors [208].